Table 8

Impact of remission and LDA on other outcomes*

Authors	Country/region	Year of publication	Patients	Follow-up years	Remission							Impact
Authors	Country/region	Year of publication	Patients	Follow-up years	Disease activity index	Immunological activity	PGA	PDN daily dose	IS use	AM use	Minimal duration	Impact
Reátegui-Sokolov et al28	Peru	2019	308	NR	SLEDAI=0	Not allowed	NR	≤5	Allowed	Allowed	At least once	Outcome: Hospitalisation HR 0.45, p=0.001
Fasano et al30	Italy	2019	294	9	C-SLEDAI=0	Allowed	NR	≤5	Allowed	Allowed	5 years	Cardiovascular event: HR 0.18, p=0.023
Authors	Country/region	Year of publication	Patients	Follow-up years	LDA								Impact
Authors	Country/region	Year of publication	Patients	Follow-up years	Disease activity index	Exclusion of new activity	Major organ exclusion	PGA	Prednisone daily dose	IS drug use	Antimalarial use	Minimal duration	Impact
Reátegui-Sokolov et al28	Peru	2019	308	NR	SLEDAI<=4	No	No	NR	<=7.5	Allowed	Allowed	At least once	Excluding remission. Outcome: Hospitalisation HR 0.50, p=0.001
Yeo et al41	Australia	2020	200	2.1	SLEDAI<=4	Yes	Yes	<1	<=7.5	Allowed	Allowed	50%	Outcome: Direct health cost. Ratio of geometric means 0.53, p<0.001

*If an article included more than one definition, a row per definition is included.
AM, antimalarials; IS, immunosuppressive drug; LDA, low disease activity; NR, not reported; PDN, prednisone; PGA, Physician Global Assessment; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.